STADA

Press Releases

Press Releases

STADA acquires Bayvit, Spain’s second-largest generic-drug company

STADA Arzneimittel AG is to acquire 100% of Bayvit S.A., Barcelona, a Spanish pharmaceutical company specializing in the marketing of generic drugs.
The sellers are the Leverkusen-based Bayer Group and the privately owned
Vita S.A., Barcelona, which presently each hold 50% of Bayvit’s capital stock.

Bayvit, which has been a market player since 1997, increased sales in 2001 by 50% to EUR 20 million, making it the second-largest supplier of generic drugs in Spain. STADA estimates that the Spanish generics market, which is still small by European standards, grew by more than 50% in 2001 to around EUR 200 million. Over the coming years, the market is expected to continue to grow at a substantial rate as generic drugs are assuming an increasingly important role in Spain, as elsewhere, in attempts to constrain costs in the healthcare sector.

The primary corporate focus of Bayvit is on marketing and distribution. It has no production or product development capabilities of its own. Of a total workforce of around 90, approximately 70 are employed in the sales force. Bayvit’s product range encompasses 27 standard generic drugs from various therapeutical areas. The continuing production of these generic drugs after the acquisition is guaranteed through contract manufacturing agreements with the previous manufacturers. For new products in future, Bayvit can draw on both the development capacities of Vita as well as the STADA Group’s Europe-wide

product development capabilities. Bayvit will continue to operate as an autonomous company in the Spanish market, working independently of the STADA distribution company Ciclum Farma, which also operates in Spain.

The acquisition of Bayvit has substantially strengthened STADA’s position in the important Spanish growth market for generic drugs, reinforcing its status as a European supplier of generic drugs. STADA anticipates record sales of well above EUR 500 million for 2001. The final figures for 2001 will be published on April 22, 2002.

For more information, please contact:

STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: communications@stada.de

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Learn more

Sustainability

Sustainability

For STADA "All the best" means taking responsibility.

Learn more

entdecken